- Additional Fast Trak sites will support cell and gene therapy industry in fast growing markets
- New online digital CELLT1 course provides cell and gene therapy manufacturing theory
December 9, 2020
Cytiva, a global life sciences leader, is expanding its offering at its Fast Trak research and training facilities in Korea, Japan, Cambridge, UK and Uppsala, Sweden. The expanded offering will support the growing cell and gene therapy industry, complementing current services provided in Shanghai, Toronto, and Marlborough, Massachusetts. Process development(PD), media and assay development, and contract development services for preclinical through Phase 1 manufacturing will now be offered at all locations.
Catarina Flyborg, Vice President, Cell and Gene Therapy, says: “Cell and gene therapies have the potential to truly transform global health. By expanding our Fast Trak services, Cytiva will play an even bigger role in accelerating the development of these novel therapeutics.”
Each site will have space dedicated solely to cell and gene therapy process development and training and will use Cytiva’s digital technologies. Working directly with experts, customers will develop processes that can improve their productivity and reduce costs. This support will assist them in bringing their novel therapeutics to market faster, while maintaining complete control and understanding of their processes.
The exponential growth of the cell and gene therapy industry has also created a need for education and training. With approximately 1,078 regenerative medicine and advanced therapy clinical trials underway globally and more 1,000 regenerative medicine companies1, continuing education is needed to ensure there is enough talent to meet industry demands. Cytiva’s Fast Trak sites will offer cell therapy manufacturing courses designed to provide the specialized training needed to meet global demand for these novel therapeutics.
Recently, Cytiva launched its first online cell therapy training program. Also held in person over three days, the online Advanced Cell Therapy Technology CELLT1 program provides a comprehensive overview of the cell and gene therapy market through a combination of theoretical and lab-based learning. The new online, self-paced program is divided into eight courses and covers upstream, cell expansion, and downstream applications.
Click here to learn more about the first online CELLT1 program.
1 Alliance for Regenerative Medicine
About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Media Contact:
Colleen Connolly
[email protected]
+ 1 774 245 3893